Retinal changes may be early sign of dementia

Article

There is a correlation between functional cell loss in the retina and signs of dementia in people who have a genetic risk for frontotemporal dementia (FTD), according to researchers from the US.

There is a correlation between functional cell loss in the retina and signs of dementia in people who have a genetic risk for frontotemporal dementia (FTD), according to researchers from the University of Alabama, Birmingham (UAB), Alabama, USA, Gladstone Institutes, and the University of California, San Francisco, California, USA.

The researchers found that changes in the retina occur much earlier than dementia-related changes appear in an individual's behaviour. Their findings were published in the Journal of Experimental Medicine.

Using an electroretinogram, the researchers compared ganglion cell activity in healthy subjects with subjects known to have frontotemporal dementia, noting a significant decrease in cell activity in the retina of subjects with dementia.

Li Gan, PhD, lead investigator at Gladstone Institutes said, "Retinal degeneration was detectable in mutation carriers prior to the onset of cognitive symptoms, establishing retinal thinning as one of the earliest observable signs of familial FTD. This means that retinal thinning could be an easily measured outcome for clinical trials."

"The results of this study show that we can use the thinning of retinal cells as a marker for this type of dementia," added Dr Eric Robertson, PhD, associate professor at UAB, Department of Vision Sciences. "Further studies may help determine whether the changes in the retina can also be utilized as a marker of disease progression."

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.